Charles River Laboratories (CRL)
Return on assets (ROA)
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Net income | US$ in thousands | 474,624 | 486,226 | 390,982 | 364,304 | 252,019 |
Total assets | US$ in thousands | 8,195,000 | 7,602,770 | 7,024,290 | 5,490,830 | 4,692,790 |
ROA | 5.79% | 6.40% | 5.57% | 6.63% | 5.37% |
December 31, 2023 calculation
ROA = Net income ÷ Total assets
= $474,624K ÷ $8,195,000K
= 5.79%
Charles River Laboratories' return on assets (ROA) has shown some fluctuations over the past five years. The ROA decreased from 6.63% in 2020 to 5.37% in 2019 before increasing to 5.57% in 2021. However, the ROA then decreased to 6.40% in 2022 and further to 5.79% in 2023. Overall, the company's ROA has generally remained above 5% during this period, indicating that the company is generating a positive return on its assets. It is important to further investigate the reasons behind the fluctuations in ROA to assess the company's asset utilization and profitability performance.
Peer comparison
Dec 31, 2023
Company name
Symbol
ROA
Charles River Laboratories
CRL
5.79%
Arrowhead Pharmaceuticals Inc
ARWR
-26.81%
Exelixis Inc
EXEL
7.06%
Incyte Corporation
INCY
8.81%
IQVIA Holdings Inc
IQV
5.09%
Medpace Holdings Inc
MEDP
17.07%